Penn State College of Medicine, Beat Childhood Cancer Research Consortium and Four Diamonds launch clinical trial that aims to combat solid tumors
In a step toward fighting solid tumors in children and young adults, Penn State College of Medicine, the Beat Childhood Cancer Research Consortium and Four Diamonds, along with Senhwa Biosciences, Inc. are launching a pioneering clinical[...]
Q&A: Finding novel therapies for childhood cancer
Since the first time she treated a child with neuroblastoma, Giselle Saulnier Sholler wanted to do the impossible for her patients. Neuroblastoma is the most common extracranial solid tumor in children with[...]
FDA approves pediatric neuroblastoma drug based on Penn State professor’s work
Giselle Saulnier Sholler, professor of pediatrics and of pharmacology, reflects on 20 years working to change cancer outcomes for children HERSHEY, Pa. — In 2003, the first year of her[...]
US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer
LOUISVILLE, Ky.--(BUSINESS WIRE)--USWM, LLC (US WorldMeds) today announced that the U.S. Food and Drug Administration (FDA) has approved IWILFIN™ (eflornithine) 192 mg tablets, a groundbreaking oral maintenance therapy for high-risk[...]
Penn State Health recruits leading researcher to fight pediatric cancer
Cris Collingwood//August 2, 2023 An internationally known physician-scientist and her research consortium have joined Penn State Health to continue efforts to eradicate pediatric cancer. Penn State Health and Penn State College of Medicine[...]
The Power of Will
Will Lacey was just a baby when doctors diagnosed a rare form of cancer and told his family there was only one end. Nobody then could imagine the journey ahead,[...]
Michigan Child Trials Target Genetic Roots of Cancers
Thank you Detroit News for featuring a story about the work we are doing. It wouldn’t be possible without the support of Dell, TGen Foundation and our generous community. Together,[...]
$1,100,000 for Beat Childhood Cancer Research!
On December 24, 2014 the Grand Rapids community surpassed the Million Dollar Challenge by raising $1,100,000 for NMTRC research! This donation was then matched by a generous Beat NB donor[...]
Endowment Gift Establishes Haworth Family Pediatric Oncology Innovative Therapeutics Clinic at Helen Devos Children’s Hospital
Children fighting cancer have new hope thanks to an endowment gift from Dick and Ethie Haworth to the Helen DeVos Children’s Hospital Foundation. Their major gift establishes the Haworth Family[...]
Research: Beat Childhood Cancer
The Beat Childhood Cancer Research Consortium is a group of 54+ universities and children's hospitals
The Advancing Neuroblastoma Research (ANR) Conference only occurs every 2 years. ANR brings together leading minds in the field of neuroblastoma from around the world and is a great place to connect with other researchers.
We’re proud to be part of this vital community driving innovation and hope for children and families affected by this disease. We always leave these meeting buzzing with ideas and outlines for exciting projects. Looking forward to 2027!
#anr2025 #neuroblastoma #washingtondc #pediatriconcology #researchisthekey
We were excited to participate in a fascinating presentation and discussion this morning on “Mastering the Molecules: Understanding Polyamine Mechanisms and Their Evolving Role in Neuroblastoma”.
It was a deep dive into the preclinical work surrounding polyamine mechanism, the role of DFMO, what is the ideal DFMO dose/combination and the future directions in polyamine research both preclinically and clinically.
#anr2025 #polyaminesresearch #dfmo #neuroblastoma
So thankful for Dr. Michael Ferguson and team (Joanna, Jun, and others) at Norton Children's Hospital and the University of Louisville School of Medicine for showing us around their lab last week!
They have some access to some pretty remarkable technology and potential therapeutic options, that we are excited to collaborate with them to advance pediatric oncology research.
Our team had the privilege of presenting three scientific posters and two oral presentations at #ASPHO2025.
Scroll to see the posters in action:
- Safety of Naxitamab + GM-CSF in Combination with Induction Chemotherapy in High-Risk Neuroblastoma
- Survival Outcomes in Patients with High-Risk Neuroblastoma in Remission 7 Years after Starting DFMO (IWILFIN®/Eflornithine) Maintenance Therapy
-Safety Comparison of Two Different Dosing Regimens for Oral Eflornithine in Pediatric Solid Tumors
The two oral presentations were:
- Dr. Sholler - Special Interest Group Physician Scientist "Investigational Trial to FDA Approval - DFMO Drug Development"
- Dr. Kraveka - "Educational Theater: FDA-Approved Anti-GD2 Cytotoxic Immunotherapy for High-Risk Neuroblastoma: Multi-center Efficacy and Safety Data Review"
ASPHO Exhibition 2025. We love connecting with our Pediatric Oncology community!
See everyone at the American Society of Pediatric Hematology/Oncology (ASPHO) this Thursday-Friday!
